Lorenza Ferrillo
Overview
Explore the profile of Lorenza Ferrillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iacotucci P, Carnovale V, Qiao D, Ferrillo L, Sanduzzi Zamparelli A, Savi D
Pediatr Pulmonol
. 2024 Oct;
60(1):e27330.
PMID: 39412420
No abstract available.
2.
Iacotucci P, Carnovale V, Ferrillo L, Somma J, Bocchino M, DIppolito M, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38276090
This study aimed to assess the main clinical and anamnestic characteristics of adult Cystic Fibrosis (CF) patients and to evaluate the association of frailty with the CF genotyping classification. In...
3.
Carnovale V, Iacotucci P, Qiao D, Ferrillo L, Somma J, Buonaurio S, et al.
Respir Med
. 2022 Sep;
202:106970.
PMID: 36058164
Background: The aim of this study was to assess the long-term clinical impact of the application of e-health as part of a virtual model of care in patients with Cystic...
4.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A, et al.
J Clin Med
. 2022 Feb;
11(4).
PMID: 35207295
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is the newest cystic fibrosis transmembrane conductance regulator () modulator drug approved for the treatment of patients with cystic fibrosis (pwCF) aged ≥6 years with at least...
5.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Medio P, Ferrillo L, et al.
Respir Med
. 2021 Oct;
189:106646.
PMID: 34673344
Background: Elexacaftor/tezacaftor/ivacaftor (E/T/I) is a cystic fibrosis transmembrane conductance regulator (CFTR) triple combination therapy used for the treatment of cystic fibrosis (CF) in patients aged ≥12 years who have at...